|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,653 GBX | +0.76% |
|
+3.38% | +13.98% |
| Apr. 25 | Sector Update: Health Care Stocks Drop in Afternoon Trading | MT |
| Apr. 25 | GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines | MT |
Nov 14 (Reuters) - GSK plc:
* GSK: ANNOUNCES POSITIVE PHASE IIA STUDY RESULTS FOR A NEW FIRST-IN-CLASS CANDIDATE MEDICINE FOR PATIENTS WITH TUBERCULOSIS
* GSK - TREATMENT WAS GENERALLY WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS IDENTIFIED
* GSK: GSK3036656 SHOWED EARLY BACTERICIDAL ACTIVITY WITH LOW, ONCE-DAILY ORAL DOSE AFTER 14 DAYS OF TREATMENT IN USERS WITH DRUG-SUSCEPTIBLE PULMONARY TB Further company coverage:
| 1st Jan change | Capi. | |
|---|---|---|
| +13.98% | 83.75B | |
| +25.83% | 653B | |
| +27.00% | 556B | |
| -6.76% | 354B | |
| +20.34% | 331B | |
| +3.00% | 296B | |
| +13.09% | 233B | |
| +5.46% | 201B | |
| -9.61% | 193B | |
| -6.26% | 144B |
GSK PLC 
